Validating blood tests for stage III lung cancer
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial is testing whether new blood tests can reliably detect and monitor stage III non-small cell lung cancer (NSCLC). It hopes to improve how doctors track your cancer and decide on treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage III non-small cell lung cancer (NSCLC), meaning it has not spread to distant organs.
- You are 18 years or older.
- You are planning to have treatment with the goal of curing your cancer (surgery or radiation).
- You must be able to understand and sign a consent form.
- You have had certain scans and lung function tests as part of your regular care.
- You have enough tumor tissue from a biopsy or surgery to provide DNA for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a blood test to detect tiny amounts of cancer DNA after standard chemoradiation can help decide if extra chemotherapy and immunotherapy is right for you. It aims to improve outcomes for people with stage 3 lung cancer that can't be removed by surgery.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Hear when a new Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.